Crinetics Pharmaceuticals CRNX Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -3,020.3%+46,549pp | -6,714.8%+25,899pp | -31,130.2%-1,605pp | -30,392.2%-10,324pp | -49,569.7%-36,998pp | |
| Net margin | -2,747.2%+40,444pp | -6,046.2%+22,674pp | -27,563.3%-815pp | -26,568.5%-7,901pp | -43,191.1%-31,263pp | |
| EBITDA margin | -2,997.5%+46,146pp | -6,664.2%+25,681pp | -30,890.2%-1,582pp | -30,144.9%-10,204pp | -49,143.9%-36,638pp | |
| Free cash flow margin | -2,321.7%+33,144pp | -4,985.5%+17,540pp | -23,337.1%-3,330pp | -22,269.8%-8,597pp | -35,465.9%-26,006pp | |
| Returns | ||||||
| Return on equity | -39.2%-8.3pp | -40.2%-8.1pp | -44.4%-4.2pp | -36.9%+10.7pp | -30.8%+9.9pp | |
| Return on assets | -35.9%-7.9pp | -36.3%-7.5pp | -39.7%-4.5pp | -33.2%+8.8pp | -28.1%+8.4pp | |
| Return on invested capital | -45.1%-1.8pp | -50.4%-9.3pp | -60.6%-0.7pp | -48.4%+21.2pp | -43.3%+20.9pp | |
| Efficiency | ||||||
| Asset turnover | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Liquidity | ||||||
| Current ratio | 18.6×-3.9× | 12.3×-10.7× | 15.1×-1.3× | 17.8×+1.7× | 22.5×+4.8× | |
| Quick ratio | 18.6×-4.0× | 12.3×-10.7× | 15.1×-1.3× | 17.8×+1.7× | 22.5×+4.8× | |
| Cash ratio | 1.6×-0.1× | 1.2×-3.3× | 1.5×-4.4× | 0.8×-4.8× | 1.7×-6.0× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | ||||||
| Book value per share | $12.30-8.7% | $10.55-35.7% | $11.38+9.4% | $12.49+18.8% | $13.47+11.3% | |
| Valuation | ||||||
| Market capitalization | $3.8B+21.9% | $4.42B-6.8% | $3.92B-4.1% | $2.9B-17.9% | $3.12B-14.4% | |
| Enterprise value | $3.74B+21.5% | $4.36B-3.6% | $3.86B+0.9% | $2.89B-11.8% | $3.08B-6.9% | |
| Price / sales | 210.5×-3,896× | 574×-3,990× | 2,555.3×-1,381× | 2,082.2×-468× | 4,106.4×+2,258× | |
| Price / book | 3×+0.5× | 4.5×+0.9× | 3.7×-1.3× | 2.5×-1.8× | 2.5×-1.7× | |
| EV / sales | 206.7×-3,840× | 567×-3,791× | 2,514.2×-1,166× | 2,079.5×-291× | 4,047.1×+2,373× | |
| Free cash flow yield | -11%-2.4pp | -8.7%-3.8pp | -9.1%-4.0pp | -10.7%-5.3pp | -8.6%-3.5pp | |
| Earnings yield | -13.1%-2.5pp | -10.5%-4.2pp | -10.8%-4.0pp | -12.8%-5.4pp | -10.5%-4.1pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Crinetics Pharmaceuticals's profit margins?
- Crinetics Pharmaceuticals (CRNX) runs a 150.0% gross margin and a -3020.3% operating margin, with a -2747.2% net margin.
- Where do Crinetics Pharmaceuticals's ratios come from?
- Every ratio is computed from Crinetics Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.